Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Syndax Pharmaceuticals (SNDX) Capital Expenditures (2016 - 2025)

Syndax Pharmaceuticals has reported Capital Expenditures over the past 5 years, most recently at $56000.0 for Q4 2025.

  • Quarterly results put Capital Expenditures at $56000.0 for Q4 2025, changed N/A from a year ago — trailing twelve months through Dec 2025 was $70000.0 (up 400.0% YoY), and the annual figure for FY2025 was $187000.0, changed.
  • Capital Expenditures for Q4 2025 was $56000.0 at Syndax Pharmaceuticals, up from $14000.0 in the prior quarter.
  • Over the last five years, Capital Expenditures for SNDX hit a ceiling of $56000.0 in Q4 2025 and a floor of $56000.0 in Q4 2025.